-
Je něco špatně v tomto záznamu ?
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
AD. Pearson, C. Rossig, C. Mackall, NN. Shah, A. Baruchel, G. Reaman, R. Ricafort, D. Heenen, A. Bassan, M. Berntgen, N. Bird, E. Bleickardt, N. Bouchkouj, P. Bross, C. Brownstein, SB. Cohen, T. de Rojas, L. Ehrlich, E. Fox, S. Gottschalk, L....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- chimerické antigenní receptory genetika MeSH
- dítě MeSH
- lékařská onkologie organizace a řízení MeSH
- lidé MeSH
- mladiství MeSH
- pediatrie MeSH
- receptory antigenů T-buněk genetika MeSH
- Úřad Spojených států pro potraviny a léky MeSH
- vyvíjení léků organizace a řízení MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
- Spojené státy americké MeSH
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children. Although the effect is of limited duration in about half of the patients, anti-CD19 CAR T-cells produce high response rates in relapsed/refractory BCP-ALL and this has highlighted previously unknown mechanisms of relapse. CAR T-cell treatment as first- or second-line therapy could also potentially benefit patients whose disease has high-risk features associated with relapse and failure of conventional therapies. Identifying patients with very early and early relapse in whom CAR T-cell therapy may replace haematopoietic stem cell transplantation and be definitive therapy versus those in whom it provides a more effective bridge to haematopoietic stem cell transplantation is a very high priority. Development of approaches to improve persistence, either by improving T cell fitness or using more humanised/fully humanised products and co-targeting of multiple antigens to prevent antigen escape, could potentially further optimise therapy. Many differences exist between paediatric B-cell non-Hodgkin lymphomas (B-NHL) and BCP-ALL. In view of the very small patient numbers with relapsed lymphoma, careful prioritisation is needed to evaluate CAR T-cells in children with Burkitt lymphoma, primary mediastinal B cell lymphoma and other NHL subtypes. Combination trials of alternative targets to CD19 (CD20 or CD22) should also be explored as a priority to improve efficacy in this population. Development of CD30 CAR T-cell immunotherapy strategies in patients with relapsed/refractory Hodgkin lymphoma will likely be most efficiently accomplished by joint paediatric and adult trials. CAR T-cell approaches are early in development for AML and T-ALL, given the unique challenges of successful immunotherapy actualisation in these diseases. At this time, CD33 and CD123 appear to be the most universal targets in AML and CD7 in T-ALL. The results of ongoing or planned first-in-human studies are required to facilitate further understanding. There are promising early results in solid tumours, particularly with GD2 targeting cell therapies in neuroblastoma and central nervous system gliomas that represent significant unmet clinical needs. Further understanding of biology is critical to success. The comparative benefits of autologous versus allogeneic CAR T-cells, T-cells engineered with T cell receptors T-cells engineered with T cell receptor fusion constructs, CAR Natural Killer (NK)-cell products, bispecific T-cell engager antibodies and antibody-drug conjugates require evaluation in paediatric malignancies. Early and proactive academia and multi-company engagement are mandatory to advance cellular immunotherapies in paediatric oncology. Regulatory advice should be sought very early in the design and preparation of clinical trials of innovative medicines, for which regulatory approval may ultimately be sought. Aligning strategic, scientific, regulatory, health technology and funding requirements from the inception of a clinical trial is especially important as these are very expensive therapies. The model for drug development for cell therapy in paediatric oncology could also involve a 'later stage handoff' to industry after early development in academic hands. Finally, and very importantly, strategies must evolve to ensure appropriate ease of access for children who need and could potentially benefit from these therapies.
Baylor College of Medicine USA
Bristol Myers Squibb Company Celgene a BMS Company USA
Chair of CAT Amsterdam Netherlands
CRISPR Therapeutics Switzerland
Erasmus University Medical Center Rotterdam Netherlands
Gracellbiotechnologies Inc China
Haematological Malignancies Co Chair Innovative Therapies for Children with Cancer Consortium Europe
Hôpital Universitaire Robert Debré and Université de Paris France
Paediatric Oncology Reference Team London UK
Pediatric Oncology Branch National Cancer Institute USA
Princess Maxima Center for Pediatric Oncology Netherlands
Seattle Children's Hospital USA
St Jude Children's Research Hospital USA
Takeda Pharmaceuticals International USA
The Andrew McDonough B Foundation USA
The Royal Marsden Hospital and the Institute of Cancer Research London UK
University Children ́s Hospital Muenster Pediatric Hematology and Oncology Germany
University Hospital Brno Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011459
- 003
- CZ-PrNML
- 005
- 20220506130515.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2021.10.016 $2 doi
- 035 __
- $a (PubMed)34840026
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pearson, Andrew Dj $u ACCELERATE, Europe. Electronic address: andy1pearson@btinternet.com
- 245 10
- $a Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration / $c AD. Pearson, C. Rossig, C. Mackall, NN. Shah, A. Baruchel, G. Reaman, R. Ricafort, D. Heenen, A. Bassan, M. Berntgen, N. Bird, E. Bleickardt, N. Bouchkouj, P. Bross, C. Brownstein, SB. Cohen, T. de Rojas, L. Ehrlich, E. Fox, S. Gottschalk, L. Hanssens, DS. Hawkins, ID. Horak, DH. Taylor, C. Johnson, D. Karres, F. Ligas, D. Ludwinski, M. Mamonkin, L. Marshall, BK. Masouleh, Y. Matloub, S. Maude, J. McDonough, V. Minard-Colin, K. Norga, K. Nysom, A. Pappo, L. Pearce, R. Pieters, M. Pule, A. Quintás-Cardama, N. Richardson, M. Schüßler-Lenz, N. Scobie, MA. Sersch, MA. Smith, J. Sterba, SK. Tasian, B. Weigel, SL. Weiner, CM. Zwaan, G. Lesa, G. Vassal
- 520 9_
- $a The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children. Although the effect is of limited duration in about half of the patients, anti-CD19 CAR T-cells produce high response rates in relapsed/refractory BCP-ALL and this has highlighted previously unknown mechanisms of relapse. CAR T-cell treatment as first- or second-line therapy could also potentially benefit patients whose disease has high-risk features associated with relapse and failure of conventional therapies. Identifying patients with very early and early relapse in whom CAR T-cell therapy may replace haematopoietic stem cell transplantation and be definitive therapy versus those in whom it provides a more effective bridge to haematopoietic stem cell transplantation is a very high priority. Development of approaches to improve persistence, either by improving T cell fitness or using more humanised/fully humanised products and co-targeting of multiple antigens to prevent antigen escape, could potentially further optimise therapy. Many differences exist between paediatric B-cell non-Hodgkin lymphomas (B-NHL) and BCP-ALL. In view of the very small patient numbers with relapsed lymphoma, careful prioritisation is needed to evaluate CAR T-cells in children with Burkitt lymphoma, primary mediastinal B cell lymphoma and other NHL subtypes. Combination trials of alternative targets to CD19 (CD20 or CD22) should also be explored as a priority to improve efficacy in this population. Development of CD30 CAR T-cell immunotherapy strategies in patients with relapsed/refractory Hodgkin lymphoma will likely be most efficiently accomplished by joint paediatric and adult trials. CAR T-cell approaches are early in development for AML and T-ALL, given the unique challenges of successful immunotherapy actualisation in these diseases. At this time, CD33 and CD123 appear to be the most universal targets in AML and CD7 in T-ALL. The results of ongoing or planned first-in-human studies are required to facilitate further understanding. There are promising early results in solid tumours, particularly with GD2 targeting cell therapies in neuroblastoma and central nervous system gliomas that represent significant unmet clinical needs. Further understanding of biology is critical to success. The comparative benefits of autologous versus allogeneic CAR T-cells, T-cells engineered with T cell receptors T-cells engineered with T cell receptor fusion constructs, CAR Natural Killer (NK)-cell products, bispecific T-cell engager antibodies and antibody-drug conjugates require evaluation in paediatric malignancies. Early and proactive academia and multi-company engagement are mandatory to advance cellular immunotherapies in paediatric oncology. Regulatory advice should be sought very early in the design and preparation of clinical trials of innovative medicines, for which regulatory approval may ultimately be sought. Aligning strategic, scientific, regulatory, health technology and funding requirements from the inception of a clinical trial is especially important as these are very expensive therapies. The model for drug development for cell therapy in paediatric oncology could also involve a 'later stage handoff' to industry after early development in academic hands. Finally, and very importantly, strategies must evolve to ensure appropriate ease of access for children who need and could potentially benefit from these therapies.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a vyvíjení léků $x organizace a řízení $7 D000076722
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lékařská onkologie $x organizace a řízení $7 D008495
- 650 _2
- $a pediatrie $7 D010372
- 650 _2
- $a receptory antigenů T-buněk $x genetika $7 D011948
- 650 _2
- $a chimerické antigenní receptory $x genetika $7 D000076962
- 650 _2
- $a Úřad Spojených států pro potraviny a léky $7 D014486
- 651 _2
- $a Evropa $7 D005060
- 651 _2
- $a Spojené státy americké $7 D014481
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Rossig, Claudia $u University Children ́s Hospital Muenster, Pediatric Hematology and Oncology, Germany
- 700 1_
- $a Mackall, Crystal $u Department of Pediatrics and Medicine, Stanford University, Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, USA
- 700 1_
- $a Shah, Nirali N $u Pediatric Oncology Branch, National Cancer Institute, USA
- 700 1_
- $a Baruchel, Andre $u Hôpital Universitaire Robert Debré (APHP) and Université de Paris, France
- 700 1_
- $a Reaman, Gregory $u US Food and Drug Administration, USA
- 700 1_
- $a Ricafort, Rosanna $u Bristol Myers Squibb Company/Celgene, a BMS Company, USA
- 700 1_
- $a Heenen, Delphine $u KickCancer, Belgium
- 700 1_
- $a Bassan, Abraham $u Syncopation Life Sciences, USA
- 700 1_
- $a Berntgen, Michael $u Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands
- 700 1_
- $a Bird, Nick $u Solving Kids' Cancer, UK
- 700 1_
- $a Bleickardt, Eric $u Novartis, USA
- 700 1_
- $a Bouchkouj, Najat $u US Food and Drug Administration, USA
- 700 1_
- $a Bross, Peter $u US Food and Drug Administration, USA
- 700 1_
- $a Brownstein, Carrie $u Cellectis, USA
- 700 1_
- $a Cohen, Sarah Beaussant $u CRISPR Therapeutics, Switzerland
- 700 1_
- $a de Rojas, Teresa $u ACCELERATE, Europe
- 700 1_
- $a Ehrlich, Lori $u US Food and Drug Administration, USA
- 700 1_
- $a Fox, Elizabeth $u St Jude Children's Research Hospital, USA
- 700 1_
- $a Gottschalk, Stephen $u St Jude Children's Research Hospital, USA
- 700 1_
- $a Hanssens, Linda $u Miltenyi Biomedicine, Germany
- 700 1_
- $a Hawkins, Douglas S $u Seattle Children's Hospital, USA
- 700 1_
- $a Horak, Ivan D $u Tessa Therapeutics, Singapore
- 700 1_
- $a Taylor, Danielle H $u Paediatric Oncology Reference Team (PORT), London, UK
- 700 1_
- $a Johnson, Courtney $u US Food and Drug Administration, USA
- 700 1_
- $a Karres, Dominik $u Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands
- 700 1_
- $a Ligas, Franca $u Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands
- 700 1_
- $a Ludwinski, Donna $u Solving Kids' Cancer, USA
- 700 1_
- $a Mamonkin, Maksim $u Baylor College of Medicine, USA
- 700 1_
- $a Marshall, Lynley $u The Royal Marsden Hospital and the Institute of Cancer Research, London, UK
- 700 1_
- $a Masouleh, Behzad K $u Kite, a Gilead Company, USA
- 700 1_
- $a Matloub, Yousif $u Takeda Pharmaceuticals International, USA
- 700 1_
- $a Maude, Shannon $u Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, USA
- 700 1_
- $a McDonough, Joe $u The Andrew McDonough B+ Foundation, USA
- 700 1_
- $a Minard-Colin, Veronique $u Department of Pediatric and Adolescent Oncology, INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- 700 1_
- $a Norga, Koen $u Antwerp University Hospital, Paediatric Committee of the European Medicines Agency, Federal Agency for Medicines and Health Products, Belgium
- 700 1_
- $a Nysom, Karsten $u Rigshospitalet, Denmark
- 700 1_
- $a Pappo, Alberto $u St Jude Children's Research Hospital, USA
- 700 1_
- $a Pearce, Laura $u GlaxoSmithKline, USA
- 700 1_
- $a Pieters, Rob $u Princess Maxima Center for Pediatric Oncology, Netherlands
- 700 1_
- $a Pule, Martin $u Autolus Limited, UK
- 700 1_
- $a Quintás-Cardama, Alfonso $u TCR(2) Therapeutics, USA
- 700 1_
- $a Richardson, Nick $u US Food and Drug Administration, USA
- 700 1_
- $a Schüßler-Lenz, Martina $u Chair of CAT (Committee for Advanced Therapies), European Medicines Agency (EMA), Amsterdam, Netherlands; Paul-Ehrlich-Institut, Germany
- 700 1_
- $a Scobie, Nicole $u Zoe4Life, Switzerland
- 700 1_
- $a Sersch, Martina A $u Gracellbiotechnologies Inc, China
- 700 1_
- $a Smith, Malcolm A $u National Cancer Institute, USA
- 700 1_
- $a Sterba, Jaroslav $u University Hospital Brno, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Tasian, Sarah K $u Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, USA
- 700 1_
- $a Weigel, Brenda $u University of Minnesota, USA
- 700 1_
- $a Weiner, Susan L $u Children's Cancer Cause, USA
- 700 1_
- $a Zwaan, Christian Michel $u Princess Maxima Center for Pediatric Oncology, Netherlands; Haematological Malignancies Co-Chair Innovative Therapies for Children with Cancer Consortium (ITCC), Europe; Erasmus University Medical Center Rotterdam, Netherlands
- 700 1_
- $a Lesa, Giovanni $u Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands
- 700 1_
- $a Vassal, Gilles $u ACCELERATE, Europe; Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 160, č. - (2022), s. 112-133
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34840026 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130508 $b ABA008
- 999 __
- $a ok $b bmc $g 1789183 $s 1162657
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 160 $c - $d 112-133 $e 20211125 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20220425
